These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

The committee's recommendation was based on data from the TROPION-Breast01 trial, which also supported the US approval of Datroway in January.

The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.